Gapping up
In reaction to strong earnings/guidance: N/A
M&A news: CHMT +16.2% (Lanxess (LNXSF) to acquire Chemtura for $33.50/share; transaction is expected to close around mid-2017), .
Other news:
In reaction to strong earnings/guidance: N/A
M&A news: CHMT +16.2% (Lanxess (LNXSF) to acquire Chemtura for $33.50/share; transaction is expected to close around mid-2017), .
Other news:
- LPCN +28.5% (reports 'positive' top-line results from a Phase 2b clinical study of LPCN 1111)
- ARRY +18.4% (Array Biopharma & Pierre Fabre announce Columbus phase 3 study of encorafenib plus binimetinib for BRAF-Mutant Melanoma met its primary endpoint)
- GWPH +11.8% (announces 'positive' results of the Phase 3 clinical trial of its Epidiolex)
- NWBO +7.1% (files for $150 mln mixed securities shelf offering)
- FATE +6.1% (confirms orphan drug designation for lead product candidate Protmune)
- AXON +5.4% (eceived Fast Track designation for its Investigational New Drug application for intepirdine)
- VKTX +4.7% (announces the presentation of data from a proof-of-concept study of VK0214)
- CRVS +4.2% (reports preclinical and preliminary clinical biomarker data of lead oral checkpoint inhibitor CPI-444)
- EXEL +2.8% (announces its partner Daiichi Sankyo (DSNKY) initiated a phase 3 pivotal trial to evaluate CS-3150 )
- NVAX +2.2% (cont strength following last week's 75% gain)
- SRPT +1.3% (Barron's profiles positive view)
Analyst comments:
- CGIX +13.6% (initiated with a Buy at Rodman & Renshaw, also enters into a strategic alliance and partnership with ApoCell)
- ARIA +3.3% (initiated with a Outperform at Leerink Partners)
- OSK +1.2% (upgraded to Overweight from Neutral at JP Morgan)
- POT +0.6% (upgraded to Positive from Neutral at Susquehanna)
- MON +0.5% (upgraded to Mkt Perform from Underperform at Bernstein)